Table 1 |
|||
|
Baseline demographic and clinical characteristics of study patient |
|||
| Variables |
Patients received antioxidants |
Patients received placebo |
p value |
| n = 36 |
n = 34 |
||
|
|
|||
| Age (y) |
62.17 ± 6.21 |
62.97 ± 5.09 |
0.559 |
|
|
|||
| Male/Female |
21/13 |
15/21 |
0.678 |
|
|
|||
| BMI |
30.10 ± 4.04 |
29.83 ± 5.06 |
0.968 |
|
|
|||
| Current smokers, n (%) |
8 (23.53%) |
10 (27.8%) |
0.684 |
|
|
|||
| Hypertension, n (%) |
25 (75.53%) |
26 (72.2%) |
0.902 |
|
|
|||
| Diabetes mellitus, n (%) |
13 (38.23%) |
9 (25%) |
0.233 |
|
|
|||
| Dyslipidemia, n (%) |
26 (76.47%) |
28 (77.8%) |
0.896 |
|
|
|||
| Obesity, n (%) |
17 (50%) |
14 (38.9%) |
0.349 |
|
|
|||
| Family history of IHD, n (%) |
26 (76.5%) |
27 (75%) |
0.886 |
|
|
|||
| Concomitant medication: |
|||
|
|
|||
| Statins (%) |
25 (73.53%) |
27 (75%) |
0.888 |
|
|
|||
| ACEIs/ARBs (%) |
19(55.88%) |
12 (33.33%) |
0.150 |
|
|
|||
| Diuretics (%) |
6 (17.64%) |
2 (5.56%) |
0.112 |
|
|
|||
| B-blockers (%) |
19 (55.89%) |
16 (44.4%) |
0.338 |
|
|
|||
| CCB-blockers (%) |
10 (29.41%) |
11 (30.56%) |
0.917 |
|
|
|||
| Aspirin (%) |
13 (38.23%) |
16 (44.45%) |
0.598 |
|
|
|||
| Baseline systolic BP (mm/Hg) |
125.2 ± 25.4 |
138.0 ± 20.8 |
0.203 |
|
|
|||
| Baseline diastolic BP (mm/Hg) |
78.4 ± 11.7 |
75.9 ± 7.8 |
0.291 |
|
|
|||
| Baseline fasting glucose (mg/dl) |
127.1 ± 52.8 |
118.9 ± 42.2 |
0.476 |
|
|
|||
| Baseline HbA1C (%) |
7.1 ± 1.7 |
6.8 ± 1.4 |
0.391 |
|
|
|||
| Baseline total cholesterol (mg/dl) |
201.5 ± 53.1 |
198.8 ± 50.8 |
0.833 |
|
|
|||
| Baseline LDL Cholesterol (mg/dl) |
117.5 ± 43.7 |
118.3 ± 47.1 |
0.945 |
|
|
|||
| Baseline HDL% |
22.1 ± 4.6 |
26.0 ± 5.4 |
0.004 |
|
|
|||
| Baseline triglycerides (mg/dl) |
189.5 ± 95.0 |
122.8 ± 56.5 |
0.001 |
|
|
|||
| Baseline hs-CRP (mg/dl) |
1.84 ± 2.9 |
1.35 ± 1.6 |
0.616 |
|
|
|||
| Baseline endothelin(fmol/ml) |
0.7 ± 2.6 |
1.4 ± 4.8 |
0.293 |
|
|
|||
| Baseline homocysteine (μmol/l) |
9.2 ± 2.8 |
8.8 ± 3.1 |
0.486 |
|
|
|||
| Baseline renin (ng/ml/hr) |
1.8 ± 3.4 |
1.5 ± 1.8 |
0.695 |
|
|
|||
| Baseline aldosteron (pg/ml) |
7.4 ± 5.6 |
6.7 ± 4.5 |
0.590 |
|
|
|||
| Baseline urine cathacholamines (mg/24 h) |
24.74 ± 22.4 |
19.5 ± 12.1 |
0.278 |
|
|
|||
|
Shargorodsky et al. Nutrition & Metabolism 2010 7:55 doi:10.1186/1743-7075-7-55 |
|||
